Glatt Air's Executive Vice-President on Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Glatt Air's Executive Vice-President on Innovation

Pharmaceutical Technology
Volume 34, Issue 4, pp. 126

Q&A with
Steve Sirabian, executive vice-president of Glatt Air Techniques


Steve Sirabian
PharmTech:
What is the biggest industry challenge you're now facing?

Sirabian:
One challenge that has received relatively little publicity is the difficulty for innovations to gain traction. Traditionally, innovation has been a hallmark of the pharmaceutical industry, but pressures such as plant closings, generic competition, and reduced pipelines have made it difficult to introduce new technologies for pharmaceutical processing. Innovations often are met with genuine interest at first, but hurdles later arise that frequently result in the somewhat reluctant abandonment of the new concept.

The difficulties begin with limited research budgets and reduced staffs, but the problems go deeper. The inherent risk of anything new means that it is difficult if not impossible to predict the return on investment (ROI) precisely. In fact, the more innovation attempted, the greater the number of failures, and a company must be willing to accept that failure rate. The industry once had the margins to absorb failures, but the current economic environment discourages such an approach.

Regulatory concerns play an equal role in suppressing innovation. One of the first questions asked about a new technology is how many validated installations are currently in operation.

In the end, the only realistic opportunity for new technologies seems to lie with new drugs. The time and cost of most manufacturing changes preclude any consideration of new processes from a practical perspective. But even here, the difficulty in forecasting the ROI may trump the processing benefits available.

PharmTech:
Do you see a new industry trend emerging?

Sirabian:
More and more projects are executed using high-level washing in place (WIP) with full cleaning in place (CIP) reserved for only the most demanding applications. CIP entails fully automated cleaning, but WIP cleans at a level greater than 90% and then relies on a manual cleaning phase. On a different note, automated machine-level controls have long been a manufacturing standard, but now I see a move toward networked applications and central servers with local slave controls.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here